Avadel Pharmaceuticals PLC (AVDL)
Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
Free AVDL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.90 out of 4) 77th percentile
(ranked higher than approx. 77% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|